Drug Trial Radar · NCT02925234
The Drug Rediscovery Protocol (DRUP Trial)
Last checked: Nov 19, 2026Latest source record: Jan 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,550
Planned (sponsor's estimate)
Start
Aug 2016
Primary completion
Sep 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- The Netherlands Cancer InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Novartis; Roche Pharma AG; Merck Sharp & Dohme LLC; Boehringer Ingelheim; Ipsen; Eisai Inc.; Pfizer; Clovis Oncology - Pharma and; Eli Lilly and Company; Janssen, LP; GlaxoSmithKline; Incyte Corporation; Dutch Cancer Society; Stelvio for Life
- First posted
- Oct 5, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, non-randomized clinical trial that aims to describe the efficacy and toxicity of commercially available, targeted anticancer drugs\* prescribed for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic or protein expression test. The study also aims to simplify patient access to approved targeted therapies that are contributed to the program by collaborating pharmaceutical companies and to perform next generation sequencing on tumor biopsies for biomarker analyses. Eligible patients have an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma for which standard treatment options are no longer available and acceptable performance status and organ function. A genomic or protein expression test must have been performed on the tumor and the results must identify at least one potentially actionable molecular variant as defined in the protocol. Results from the molecular profiling test will be used to determine an appropriate drug(s) from among those available in the protocol. The choice of drug will be supported by a list of potential profiles, a molecular tumor board, a knowledge library and by study coordinators for review and approval of the match. The protocol-specified treatment will be administered to the patient once any drug-specific eligibility criteria are confirmed and a fresh pre-treatment biopsy is performed for future genetic studies. All patients who receive treatment with a drug available in the protocol will be followed for standard efficacy outcomes including tumor response, progression-free and overall survival as well as duration of treatment. In addition, treatment related toxicity will be evaluated.
Conditions
- Cancer
- Tumors
- Neoplasm
- Neoplasia
Interventions
PanitumumabDrug
Panitumumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of panitumumab might be expected based on their molecular tumor profile.
OlaparibDrug
Olaparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of olaparib might be expected based on their molecular tumor profile.
DabrafenibDrug
Dabrafenib treatment for patients with an mutated advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of dabrafenib might be expected based on their molecular tumor profile.
NilotinibDrug
Nilotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of nilotinib might be expected based on their molecular tumor profile.
TrametinibDrug
Trametinib treatment for patients with an mutated advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of trametinib might be expected based on their molecular tumor profile.
ErlotinibDrug
Erlotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of erlotinib might be expected based on their molecular tumor profile.
Trastuzumab and Pertuzumab (combination treatment)Drug
Trastuzumab and Pertuzumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of trastuzumab + pertuzumab might be expected based on their molecular tumor profile.
Vemurafenib and Cobimetinib (combination treatment)Drug
Vemurafenib + Cobimetinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Vemurafenib + Cobimetinib might be expected based on their molecular tumor profile.
VismodegibDrug
Vismodegib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of vismodegib might be expected based on their molecular tumor profile.
RegorafenibDrug
Regorafenib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of vismodegib might be expected based on their molecular tumor profile.
NivolumabDrug
Nivolumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of nivolumab might be expected based on their molecular tumor profile.
AfatinibDrug
Afatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Afatinib might be expected based on their molecular tumor profile.
Dabrafenib and trametinibDrug
Dabrafenib + trametinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Dabrafenib + Trametinib might be expected based on their molecular tumor profile.
RibociclibDrug
Ribociclib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Ribociclib might be expected based on their molecular tumor profile.
LenvatinibDrug
Lenvatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Lenvatinib might be expected based on their molecular tumor profile.
PembrolizumabDrug
Pembrolizumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Pembrolizumab might be expected based on their molecular tumor profile.
DurvalumabDrug
Durvalumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Durvalumab might be expected based on their molecular tumor profile.
RucaparibDrug
Rucaparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Rucaparib might be expected based on their molecular tumor profile.
AxitinibDrug
Axitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Axitinib might be expected based on their molecular tumor profile.
PalbociclibDrug
Palbociclib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Palbociclib might be expected based on their molecular tumor profile.
CrizotinibDrug
Crizotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Crizotinib might be expected based on their molecular tumor profile.
SunitinibDrug
Sunitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Sunitinib might be expected based on their molecular tumor profile.
CabozantinibDrug
Cabozantinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Cabozantinib might be expected based on their molecular tumor profile.
AbemaciclibDrug
Abemaciclib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Abemaciclib might be expected based on their molecular tumor profile.
AlectinibDrug
Alectinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Alectinib might be expected based on their molecular tumor profile.
Atezolizumab and BevacizumabDrug
Atezolizumab + Bevacizumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Atezolizumab + Bevacizumab might be expected based on their molecular tumor profile.
Ipilimumab and nivolumabDrug
Ipilimumab+nivolumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of ipilimimab + nivolumab might be expected based on their molecular tumor profile.
EntrectinibDrug
Entrectinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of entrectinib might be expected based on their molecular tumor profile.
TalazoparibDrug
Talazoparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of talazoparib might be expected based on their molecular tumor profile.
DacomitinibDrug
Dacomitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of dacomitinib might be expected based on their molecular tumor profile.
LorlatinibDrug
Lorlatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of lorlatinib might be expected based on their molecular tumor profile.
ErdafitinibDrug
Erdafitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of erdafitinib might be expected based on their molecular tumor profile.
AlpelisibDrug
Alpelisib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of alpelisib might be expected based on their molecular tumor profile.
NiraparibDrug
Niraparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of niraparib might be expected based on their molecular tumor profile.
PemigatinibDrug
Pemigatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of pemigatinib might be expected based on their molecular tumor profile.
SelpercatinibDrug
Selpercatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of selpercatinib might be expected based on their molecular tumor profile.
TepotinibDrug
Tepotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of tepotinib might be expected based on their molecular tumor profile.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of patients that are treated based on their molecular tumor profileTime frame: 6 months after treatment initiation (estimated average)
- Objective tumor responseTime frame: 6 months after treatment initiation (estimated average)
- Stable diseaseTime frame: 6 months after treatment initiation (estimated average)
- Treatment-related grade≥3 and serious adverse eventsTime frame: 6 months after treatment initiation (estimated average)
Locations
36 sites in 1 country. Site status is shown where the registry gives one.
Noordwest ziekenhuisgroep Alkmaar (NWZ)
Alkmaar, Netherlands · Recruiting
Ziekenhuisgroep Twente
Almelo, Netherlands · Recruiting
Meander medisch centrum
Amersfoort, Netherlands · Recruiting
Netherlands Cancer Institute
Amsterdam, Netherlands · Recruiting
Amsterdam UMC, locatie VUmc
Amsterdam, Netherlands · Recruiting
Amsterdam UMC, locatie AMC
Amsterdam, Netherlands · Active not recruiting
Onze Lieve Vrouwe Gasthuis (OLVG)
Amsterdam, Netherlands · Recruiting
Gelre ziekenhuizen
Apeldoorn, Netherlands · Recruiting
Rijnstate ziekenhuis
Arnhem, Netherlands · Recruiting
Amphia Ziekenhuis
Breda, Netherlands · Recruiting
Reiner de Graaf Gasthuis
Delft, Netherlands · Recruiting
Deventer ziekenhuis
Deventer, Netherlands · Recruiting
Nij Smellinghe Ziekenhuis
Drachten, Netherlands · Recruiting
Ziekenhuis Gelderse Vallei
Ede, Netherlands · Recruiting
Maxima Medisch Centrum
Eindhoven, Netherlands · Recruiting
Zuyderland medisch centrum
Geleen, Netherlands · Recruiting
Rivas zorggroep
Gorinchem, Netherlands · Recruiting
Martini ziekenhuis
Groningen, Netherlands · Recruiting
University Medical Center Groningen
Groningen, Netherlands · Recruiting
Spaarne gasthuis
Haarlem, Netherlands · Recruiting
Tergooi MC
Hilversum, Netherlands · Not yet recruiting
Treant zorggroep
Hoogeveen, Netherlands · Recruiting
Medisch Centrum Leeuwaarden
Leeuwarden, Netherlands · Recruiting
Leiden University Medical Center
Leiden, Netherlands · Recruiting
Maastricht University Medical Center
Maastricht, Netherlands · Recruiting
St. Antonius ziekenhuis
Nieuwegein, Netherlands · Recruiting
Radboud umc
Nijmegen, Netherlands · Recruiting
Bravis ziekenhuis
Roosendaal, Netherlands · Recruiting
St. Fransicus Gasthuis
Rotterdam, Netherlands · Recruiting
Erasmus MC
Rotterdam, Netherlands · Recruiting
Haaglanden medisch centrum
The Hague, Netherlands · Recruiting
Haga ziekenhuis
The Hague, Netherlands · Recruiting
Elisabeth-TweeSteden Ziekenhuis
Tilburg, Netherlands · Recruiting
University Medical Center Utrecht
Utrecht, Netherlands · Recruiting
VieCuri medisch centrum
Venlo, Netherlands · Recruiting
Isala klinieken
Zwolle, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.